KRASG12C mutant lung adenocarcinoma unique biology, novel therapies and new challenges /
KRAS mutant lung cancer is the most prevalent molecular subclass of adenocarcinoma (LUAD), which is a heterogenous group depending on the mutation-type which affects not only the function of the oncogene but affects the biological behavior of the cancer as well. Furthermore, KRAS mutation affects ra...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2024
|
| Sorozat: | PATHOLOGY AND ONCOLOGY RESEARCH
29 |
| Tárgyszavak: | |
| doi: | 10.3389/pore.2023.1611580 |
| mtmt: | 34531676 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/29867 |
| Tartalmi kivonat: | KRAS mutant lung cancer is the most prevalent molecular subclass of adenocarcinoma (LUAD), which is a heterogenous group depending on the mutation-type which affects not only the function of the oncogene but affects the biological behavior of the cancer as well. Furthermore, KRAS mutation affects radiation sensitivity but leads also to bevacizumab and bisphosphonate resistance as well. It was highly significant that allele specific irreversible inhibitors have been developed for the smoking associated G12C mutant KRAS (sotorasib and adagrasib). Based on trial data both sotorasib and adagrasib obtained conditional approval by FDA for the treatment of previously treated advanced LUAD. Similar to other target therapies, clinical administration of KRASG12C inhibitors (sotorasib and adagrasib) resulted in acquired resistance due to various genetic changes not only in KRAS but in other oncogenes as well. Recent clinical studies are aiming to increase the efficacy of G12C inhibitors by novel combination strategies. |
|---|---|
| Terjedelem/Fizikai jellemzők: | 9 |
| ISSN: | 1219-4956 |